Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Novabev Group reported for 3 months of 2024 by RAS

5/7/24 BELU

Ingrad reported for the 3 months of 2023 by RAS

5/7/24 INGR

Seligdar started installation of process equipment at Hvoynoye

5/7/24 SELG

Lenenergo may buy LOESK

5/7/24 LSNG

Lenenergo reported for 3 months of 2024 by RAS

5/6/24 LSNG

Levenguc reported for 2023 by IFRS

5/6/24 LVHK

Tatneft reported for 3 months of 2024 by RAS

5/6/24 TATN

M.Video launched the retailer's first multi-brand smartphone zones

5/6/24 MVID

Levenguc reported for 3 months of 2024 by RAS

5/6/24 LVHK

MTS reported for 2023 by RAS

5/6/24 MTSS